Laser-induced fluorescence detection of stomach cancer using hypericin

Dets, Sergiy M.; Buryi, Alexander N.; Melnik, Ivan S.; Joffe, Alexander Y.; Rusina, Tatyana V.

doi:10.1117/12.260819

Cited by 12 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A tissue distribution and serum analysis conducted at 1, 8 and 24 h following HYP administration (5 mg/kg PO) showed that HYP was well absorbed and distributed within 1 h of administration, and its rate of elimination from the tumor over 24 h was significantly slower than that observed in other tissues. This suggests that the LNCaP prostate tumor xenograft is exposed to HYP when dosed orally at 5 mg/kg, and as the literature reports (19) HYP may actually accumulate in cancer cells. Interestingly, the serum data indicates that HYP remains in the serum after 24 h at levels comparable to those determined at 8 h.…”

Section: Discussionmentioning

confidence: 73%

“…HYP was observed to be toxic to both cell lines only in the presence of photoirradiation. An attractive feature of HYP is its ability to be taken up rapidly by cancer cells and, due to its fluorescence upon excitation by UV or blue-visible light, is sometimes used for the early detection of stomach cancer (19). We believe that if, as evidence in the literature suggests, HYP is selectively accumulated in cancer cells (19), there is enormous potential for the development of this compound as a photocytotoxic therapeutic agent for use in prostate cancer PDT.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tumor-specific and Photodependent Cytotoxicity of Hypericin in the Human LNCaP Prostate Tumor Model

Xie¹,

Hudson²,

Guns³

2001

Photochem Photobiol

View full text Add to dashboard Cite

Hypericin (HYP) has been reported to have photodependent cytotoxic activity in a variety of cancer cell lines. However, this activity has yet to be rigorously tested in vivo in tumor models. In this study LNCaP, PC-3 and DU-145 cells were used to test the cytotoxic effects of HYP in vitro, precursory to an in vivo study designed to investigate the effects of HYP in an established murine model for prostate cancer. Specifically, the model used employs immunocompromised nude mice bearing the LNCaP solid tumor xenograft. In vitro cytotoxicity experiments indicated that the dose causing 50% lethality for HYP in LNCaP, PC-3 and DU-145 cells were 2.07, 2.15 and 2.23 microM, respectively, following irradiation with red light (590 nm) for 30 min at a fluence rate of 0.1 J/cm2/s. Cells treated with HYP in the absence of photoirradiation showed no signs of cytotoxicity. A tissue distribution study was also carried out using the LNCaP solid tumor model to determine whether or not HYP is distributed to the target tissue. HYP was broadly distributed in tissues studied, including LNCaP tumor xenograft tissue. Furthermore, tumor tissue eliminated HYP at a slower rate than any of the other tissues examined. Interestingly, HYP levels were maintained in serum 24 h after oral administration (5 mg/kg dose). A pilot study designed to examine the efficacy of HYP treatment in nude mice bearing LNCaP tumors conducted over 28 days suggested that HYP, in combination with photoirradiation, inhibits both tumor growth and the elevation of prostate-specific antigen levels. Although the results reported for the current studies are preliminary they do provide evidence for an application of HYP PDT to prostate cancer which warrants further investigation.

show abstract

Section: Discussionmentioning

confidence: 73%

Section: Introductionmentioning

confidence: 99%

Tumor-specific and Photodependent Cytotoxicity of Hypericin in the Human LNCaP Prostate Tumor Model

Xie¹,

Hudson²,

Guns³

2001

Photochem Photobiol

View full text Add to dashboard Cite

show abstract

“…In addition, hypericin has also attracted attention for its antidepressant functions (10)(11)(12). Hypencin has been shown to have a remarkably fast uptake by cancer cells, strong photopotentiation against EMT-6/ED neoplastic cells (13) and has been used in clinical trials for the detection of stomach cancers (14). Fluorescence measurements using confocal microscopy have located hypericin in the membrane, cytoplasm and nucleus of T47D mammary tumor cells (15).…”

Section: Introductionmentioning

confidence: 99%

Subcellular Distributions and Excited‐State Processes of Hypericin in Neurons

English

Doyle

Petrich

1999

Photochem & Photobiology

View full text Add to dashboard Cite

The photodynamic drug, hypericin, is studied in fetal rat neurons using fluorescence microscopy. Hypericin has an extremely high affinity for the cell membrane and is found to a smaller extent in the nucleus. Fluorescent excitation of hypericin is shown to cause irreversible damage to the cell membranes of living neurons. Fixed cells were used to make ultrafast time-resolved measurements to avoid the deleterious effects of long-term exposure to intense light and room temperatures. To our knowledge, these are the first ultrafast time-resolved measurements of the fluorescence lifetime of hypericin in a subcellular environment. Nonexponential fluorescence decay is observed in hypericin in the neurons. This nonexponential decay is discussed in terms of other examples where nonexponential decay is induced in hypericin upon its binding to biomolecules. The nonradiative processes giving rise to the nonexponential hypericin decay are attributed to excited-state electron transfer, excited-state proton transfer or both. . 4 c k~z o t~~~e r~~~r r~~r , I t s -J .~.~.

show abstract

“…Thereafter, studies of HY mostly focused on the detection of bladder cancer 14,43,81. Apart from bladder screening, the applications of HY were also extended to diagnosing other types of cancers including oral cancer88 and stomach cancer 15,58. The following sub-sections will mainly discuss about the development of instrumentation and data processing for HY-PDD of bladder and oral cancer.…”

Section: Hypericin-mediated Pdd Of Cancer With Vital Fluorescence Tecmentioning

confidence: 99%

New Frontier in Hypericin-Mediated Diagnosis of Cancer with Current Optical Technologies

2011

View full text Add to dashboard Cite

Photosensitizers (PSs) have shown great potentials as molecular contrast agents in photodynamic diagnosis (PDD) of cancer. While the diagnostic values of PSs have been proven previously, little efforts have been put into developing optical imaging and diagnostic algorithms. In this article, we review the recent development of optical probes that have been used in conjunction with a potent PS, hypericin (HY). Various fluorescence techniques such as laser confocal microscopy, fluorescence urine cytology, endoscopy and endomicroscopy are covered. We will also discuss about image processing and classification approaches employed for accurate PDD. We anticipate that continual efforts in these developments could lead to an objective PDD and complete surgical clearance of tumors. Recent advancements in nanotechnology have also opened new horizons for PSs. The use of biocompatible gold nanoparticles as carrier for enhanced targeted delivery of HY has been attained. In addition, plasmonic properties of nanoparticles were harnessed to induce localized hyperthermia and to manage the release of PS molecules, enabling a better therapeutic outcome of a combined photodynamic and photothermal therapy. Finally, we discuss how nanoparticles can be used as contrast agents for other optical techniques such as optical coherence tomography and surface-enhanced Raman scattering imaging.

show abstract

Laser-induced fluorescence detection of stomach cancer using hypericin

Cited by 12 publications

References 0 publications

Tumor-specific and Photodependent Cytotoxicity of Hypericin in the Human LNCaP Prostate Tumor Model

Tumor-specific and Photodependent Cytotoxicity of Hypericin in the Human LNCaP Prostate Tumor Model

Subcellular Distributions and Excited‐State Processes of Hypericin in Neurons

New Frontier in Hypericin-Mediated Diagnosis of Cancer with Current Optical Technologies

Contact Info

Product

Resources

About